Loading…
Repeated KI Prophylaxis in Case of Prolonged Exposure to Iodine Radioisotopes: Pharmacokinetic Studies in Adult Rats
Purpose To propose a new and effective dose regimen for stable potassium iodide (KI) repeated prophylaxis in case of prolonged exposure to radioactive iodine. Methods The pharmacokinetics of iodine was determined in rats by compartmental analyses after intravenous and oral administrations of the opt...
Saved in:
| Published in: | Pharmaceutical research 2018-12, Vol.35 (12), p.227-12, Article 227 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c516t-be64371e731940b489320dc7afafd882596ab5564eadabdc0c74a855fac3bf013 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c516t-be64371e731940b489320dc7afafd882596ab5564eadabdc0c74a855fac3bf013 |
| container_end_page | 12 |
| container_issue | 12 |
| container_start_page | 227 |
| container_title | Pharmaceutical research |
| container_volume | 35 |
| creator | Phan, Guillaume Chioukh, Rym Suhard, David Legrand, Alexandre Moulin, Charlotte Sontag, Thibaud Rebière, François Bouvier-Capely, Céline Agarande, Michelle Renaud-Salis, Valérie Jourdain, Jean-René |
| description | Purpose
To propose a new and effective dose regimen for stable potassium iodide (KI) repeated prophylaxis in case of prolonged exposure to radioactive iodine.
Methods
The pharmacokinetics of iodine was determined in rats by compartmental analyses after intravenous and oral administrations of the optimal dose of 1 mg/kg KI, which was previously selected in a dose-effect study. The thyroid protection against iodine-125 incorporation was followed during 24 h after a single oral dosing of KI. A repeated KI prophylaxis was modeled using initial estimates of iodine pharmacokinetic parameters.
Results
A dose regimen consisting in administrations of 1 mg/kg daily for 8 days was selected and studied. Plasma iodine concentrations predicted by simulation were verified by experimental data and varied after the third dose of KI between 174 and 1190 μg/l. The inhibition study of iodine-125 binding in the thyroid as a function of the time showed that the protection effect of KI could be correlated to stable iodine plasma concentrations. Hence, a theoretical decrease in iodine-125 thyroid uptake from 63 to 88% could be achieved in a 24 h-interval between two KI doses.
Conclusion
Given the satisfactory levels of thyroid protection, this dose regimen could be envisaged in order to extent KI indications for repeated prophylaxis. |
| doi_str_mv | 10.1007/s11095-018-2515-1 |
| format | article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02881796v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A724210167</galeid><sourcerecordid>A724210167</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-be64371e731940b489320dc7afafd882596ab5564eadabdc0c74a855fac3bf013</originalsourceid><addsrcrecordid>eNp1kk9v1DAQxS0EotvCB-CCInGBQ8o4jmOH22pV6IqVqApI3CzHdrouSZzaDmq_fZ2mlD8C-WBp5jdPbzQPoRcYjjEAexswhprmgHleUExz_AitMGUkr6H89hitgBVlzlmJD9BhCJcAwHFdPkUHBIqaE05WKJ6b0chodPZxm515N-5vOnltQ2aHbCODyVw7lzs3XCTm5Hp0YfImiy7bOm0Hk51LbZ0NLrrRhHfZ2V76Xir3PfWiVdnnOGlr7uTWeupi4mN4hp60sgvm-f1_hL6-P_myOc13nz5sN-tdriiuYt6YqiQMG0aSa2hKXpMCtGKyla3mvKB1JRtKq9JILRutQLFSckpbqUjTAiZH6M2iu5edGL3tpb8RTlpxut6JuQYF55jV1Y-Zfb2wo3dXkwlR9DYo03VyMG4KosCYEV6XZEZf_YVeuskPaZM7Ciogv1MXsjPCDq2LXqpZVKzTXQoMuGKJOv4HlZ42vVVuMK1N9T8G8DKgvAvBm_ZhMQxiToVYUiFSKsScCjFbeXlveGp6ox8mfsYgAcUChNRKl_a_Nvq_6i0t17_C</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2117060331</pqid></control><display><type>article</type><title>Repeated KI Prophylaxis in Case of Prolonged Exposure to Iodine Radioisotopes: Pharmacokinetic Studies in Adult Rats</title><source>Springer Nature</source><creator>Phan, Guillaume ; Chioukh, Rym ; Suhard, David ; Legrand, Alexandre ; Moulin, Charlotte ; Sontag, Thibaud ; Rebière, François ; Bouvier-Capely, Céline ; Agarande, Michelle ; Renaud-Salis, Valérie ; Jourdain, Jean-René</creator><creatorcontrib>Phan, Guillaume ; Chioukh, Rym ; Suhard, David ; Legrand, Alexandre ; Moulin, Charlotte ; Sontag, Thibaud ; Rebière, François ; Bouvier-Capely, Céline ; Agarande, Michelle ; Renaud-Salis, Valérie ; Jourdain, Jean-René</creatorcontrib><description>Purpose
To propose a new and effective dose regimen for stable potassium iodide (KI) repeated prophylaxis in case of prolonged exposure to radioactive iodine.
Methods
The pharmacokinetics of iodine was determined in rats by compartmental analyses after intravenous and oral administrations of the optimal dose of 1 mg/kg KI, which was previously selected in a dose-effect study. The thyroid protection against iodine-125 incorporation was followed during 24 h after a single oral dosing of KI. A repeated KI prophylaxis was modeled using initial estimates of iodine pharmacokinetic parameters.
Results
A dose regimen consisting in administrations of 1 mg/kg daily for 8 days was selected and studied. Plasma iodine concentrations predicted by simulation were verified by experimental data and varied after the third dose of KI between 174 and 1190 μg/l. The inhibition study of iodine-125 binding in the thyroid as a function of the time showed that the protection effect of KI could be correlated to stable iodine plasma concentrations. Hence, a theoretical decrease in iodine-125 thyroid uptake from 63 to 88% could be achieved in a 24 h-interval between two KI doses.
Conclusion
Given the satisfactory levels of thyroid protection, this dose regimen could be envisaged in order to extent KI indications for repeated prophylaxis.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-018-2515-1</identifier><identifier>PMID: 30298383</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Computer simulation ; Exposure ; Intravenous administration ; Iodides ; Iodine ; Iodine 125 ; Iodine isotopes ; Iodine radioisotopes ; Life Sciences ; Medical Law ; Nuclear energy ; Parameter estimation ; Pharmaceutical sciences ; Pharmacokinetics ; Pharmacology ; Pharmacology/Toxicology ; Pharmacy ; Potassium ; Potassium iodide ; Potassium iodides ; Prophylaxis ; Radioisotopes ; Rats ; Research Paper ; Thyroid ; Thyroid gland</subject><ispartof>Pharmaceutical research, 2018-12, Vol.35 (12), p.227-12, Article 227</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>COPYRIGHT 2018 Springer</rights><rights>Pharmaceutical Research is a copyright of Springer, (2018). All Rights Reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-be64371e731940b489320dc7afafd882596ab5564eadabdc0c74a855fac3bf013</citedby><cites>FETCH-LOGICAL-c516t-be64371e731940b489320dc7afafd882596ab5564eadabdc0c74a855fac3bf013</cites><orcidid>0000-0001-7223-0559 ; 0000-0001-5225-4115 ; 0000-0002-8794-9862</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30298383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02881796$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Phan, Guillaume</creatorcontrib><creatorcontrib>Chioukh, Rym</creatorcontrib><creatorcontrib>Suhard, David</creatorcontrib><creatorcontrib>Legrand, Alexandre</creatorcontrib><creatorcontrib>Moulin, Charlotte</creatorcontrib><creatorcontrib>Sontag, Thibaud</creatorcontrib><creatorcontrib>Rebière, François</creatorcontrib><creatorcontrib>Bouvier-Capely, Céline</creatorcontrib><creatorcontrib>Agarande, Michelle</creatorcontrib><creatorcontrib>Renaud-Salis, Valérie</creatorcontrib><creatorcontrib>Jourdain, Jean-René</creatorcontrib><title>Repeated KI Prophylaxis in Case of Prolonged Exposure to Iodine Radioisotopes: Pharmacokinetic Studies in Adult Rats</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><addtitle>Pharm Res</addtitle><description>Purpose
To propose a new and effective dose regimen for stable potassium iodide (KI) repeated prophylaxis in case of prolonged exposure to radioactive iodine.
Methods
The pharmacokinetics of iodine was determined in rats by compartmental analyses after intravenous and oral administrations of the optimal dose of 1 mg/kg KI, which was previously selected in a dose-effect study. The thyroid protection against iodine-125 incorporation was followed during 24 h after a single oral dosing of KI. A repeated KI prophylaxis was modeled using initial estimates of iodine pharmacokinetic parameters.
Results
A dose regimen consisting in administrations of 1 mg/kg daily for 8 days was selected and studied. Plasma iodine concentrations predicted by simulation were verified by experimental data and varied after the third dose of KI between 174 and 1190 μg/l. The inhibition study of iodine-125 binding in the thyroid as a function of the time showed that the protection effect of KI could be correlated to stable iodine plasma concentrations. Hence, a theoretical decrease in iodine-125 thyroid uptake from 63 to 88% could be achieved in a 24 h-interval between two KI doses.
Conclusion
Given the satisfactory levels of thyroid protection, this dose regimen could be envisaged in order to extent KI indications for repeated prophylaxis.</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Computer simulation</subject><subject>Exposure</subject><subject>Intravenous administration</subject><subject>Iodides</subject><subject>Iodine</subject><subject>Iodine 125</subject><subject>Iodine isotopes</subject><subject>Iodine radioisotopes</subject><subject>Life Sciences</subject><subject>Medical Law</subject><subject>Nuclear energy</subject><subject>Parameter estimation</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Potassium</subject><subject>Potassium iodide</subject><subject>Potassium iodides</subject><subject>Prophylaxis</subject><subject>Radioisotopes</subject><subject>Rats</subject><subject>Research Paper</subject><subject>Thyroid</subject><subject>Thyroid gland</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kk9v1DAQxS0EotvCB-CCInGBQ8o4jmOH22pV6IqVqApI3CzHdrouSZzaDmq_fZ2mlD8C-WBp5jdPbzQPoRcYjjEAexswhprmgHleUExz_AitMGUkr6H89hitgBVlzlmJD9BhCJcAwHFdPkUHBIqaE05WKJ6b0chodPZxm515N-5vOnltQ2aHbCODyVw7lzs3XCTm5Hp0YfImiy7bOm0Hk51LbZ0NLrrRhHfZ2V76Xir3PfWiVdnnOGlr7uTWeupi4mN4hp60sgvm-f1_hL6-P_myOc13nz5sN-tdriiuYt6YqiQMG0aSa2hKXpMCtGKyla3mvKB1JRtKq9JILRutQLFSckpbqUjTAiZH6M2iu5edGL3tpb8RTlpxut6JuQYF55jV1Y-Zfb2wo3dXkwlR9DYo03VyMG4KosCYEV6XZEZf_YVeuskPaZM7Ciogv1MXsjPCDq2LXqpZVKzTXQoMuGKJOv4HlZ42vVVuMK1N9T8G8DKgvAvBm_ZhMQxiToVYUiFSKsScCjFbeXlveGp6ox8mfsYgAcUChNRKl_a_Nvq_6i0t17_C</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Phan, Guillaume</creator><creator>Chioukh, Rym</creator><creator>Suhard, David</creator><creator>Legrand, Alexandre</creator><creator>Moulin, Charlotte</creator><creator>Sontag, Thibaud</creator><creator>Rebière, François</creator><creator>Bouvier-Capely, Céline</creator><creator>Agarande, Michelle</creator><creator>Renaud-Salis, Valérie</creator><creator>Jourdain, Jean-René</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><general>American Association of Pharmaceutical Scientists</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0001-7223-0559</orcidid><orcidid>https://orcid.org/0000-0001-5225-4115</orcidid><orcidid>https://orcid.org/0000-0002-8794-9862</orcidid></search><sort><creationdate>20181201</creationdate><title>Repeated KI Prophylaxis in Case of Prolonged Exposure to Iodine Radioisotopes: Pharmacokinetic Studies in Adult Rats</title><author>Phan, Guillaume ; Chioukh, Rym ; Suhard, David ; Legrand, Alexandre ; Moulin, Charlotte ; Sontag, Thibaud ; Rebière, François ; Bouvier-Capely, Céline ; Agarande, Michelle ; Renaud-Salis, Valérie ; Jourdain, Jean-René</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-be64371e731940b489320dc7afafd882596ab5564eadabdc0c74a855fac3bf013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Computer simulation</topic><topic>Exposure</topic><topic>Intravenous administration</topic><topic>Iodides</topic><topic>Iodine</topic><topic>Iodine 125</topic><topic>Iodine isotopes</topic><topic>Iodine radioisotopes</topic><topic>Life Sciences</topic><topic>Medical Law</topic><topic>Nuclear energy</topic><topic>Parameter estimation</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Potassium</topic><topic>Potassium iodide</topic><topic>Potassium iodides</topic><topic>Prophylaxis</topic><topic>Radioisotopes</topic><topic>Rats</topic><topic>Research Paper</topic><topic>Thyroid</topic><topic>Thyroid gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Phan, Guillaume</creatorcontrib><creatorcontrib>Chioukh, Rym</creatorcontrib><creatorcontrib>Suhard, David</creatorcontrib><creatorcontrib>Legrand, Alexandre</creatorcontrib><creatorcontrib>Moulin, Charlotte</creatorcontrib><creatorcontrib>Sontag, Thibaud</creatorcontrib><creatorcontrib>Rebière, François</creatorcontrib><creatorcontrib>Bouvier-Capely, Céline</creatorcontrib><creatorcontrib>Agarande, Michelle</creatorcontrib><creatorcontrib>Renaud-Salis, Valérie</creatorcontrib><creatorcontrib>Jourdain, Jean-René</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Phan, Guillaume</au><au>Chioukh, Rym</au><au>Suhard, David</au><au>Legrand, Alexandre</au><au>Moulin, Charlotte</au><au>Sontag, Thibaud</au><au>Rebière, François</au><au>Bouvier-Capely, Céline</au><au>Agarande, Michelle</au><au>Renaud-Salis, Valérie</au><au>Jourdain, Jean-René</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repeated KI Prophylaxis in Case of Prolonged Exposure to Iodine Radioisotopes: Pharmacokinetic Studies in Adult Rats</atitle><jtitle>Pharmaceutical research</jtitle><stitle>Pharm Res</stitle><addtitle>Pharm Res</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>35</volume><issue>12</issue><spage>227</spage><epage>12</epage><pages>227-12</pages><artnum>227</artnum><issn>0724-8741</issn><eissn>1573-904X</eissn><abstract>Purpose
To propose a new and effective dose regimen for stable potassium iodide (KI) repeated prophylaxis in case of prolonged exposure to radioactive iodine.
Methods
The pharmacokinetics of iodine was determined in rats by compartmental analyses after intravenous and oral administrations of the optimal dose of 1 mg/kg KI, which was previously selected in a dose-effect study. The thyroid protection against iodine-125 incorporation was followed during 24 h after a single oral dosing of KI. A repeated KI prophylaxis was modeled using initial estimates of iodine pharmacokinetic parameters.
Results
A dose regimen consisting in administrations of 1 mg/kg daily for 8 days was selected and studied. Plasma iodine concentrations predicted by simulation were verified by experimental data and varied after the third dose of KI between 174 and 1190 μg/l. The inhibition study of iodine-125 binding in the thyroid as a function of the time showed that the protection effect of KI could be correlated to stable iodine plasma concentrations. Hence, a theoretical decrease in iodine-125 thyroid uptake from 63 to 88% could be achieved in a 24 h-interval between two KI doses.
Conclusion
Given the satisfactory levels of thyroid protection, this dose regimen could be envisaged in order to extent KI indications for repeated prophylaxis.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30298383</pmid><doi>10.1007/s11095-018-2515-1</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-7223-0559</orcidid><orcidid>https://orcid.org/0000-0001-5225-4115</orcidid><orcidid>https://orcid.org/0000-0002-8794-9862</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-8741 |
| ispartof | Pharmaceutical research, 2018-12, Vol.35 (12), p.227-12, Article 227 |
| issn | 0724-8741 1573-904X |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02881796v1 |
| source | Springer Nature |
| subjects | Biochemistry Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Computer simulation Exposure Intravenous administration Iodides Iodine Iodine 125 Iodine isotopes Iodine radioisotopes Life Sciences Medical Law Nuclear energy Parameter estimation Pharmaceutical sciences Pharmacokinetics Pharmacology Pharmacology/Toxicology Pharmacy Potassium Potassium iodide Potassium iodides Prophylaxis Radioisotopes Rats Research Paper Thyroid Thyroid gland |
| title | Repeated KI Prophylaxis in Case of Prolonged Exposure to Iodine Radioisotopes: Pharmacokinetic Studies in Adult Rats |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T22%3A54%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repeated%20KI%20Prophylaxis%20in%20Case%20of%20Prolonged%20Exposure%20to%20Iodine%20Radioisotopes:%20Pharmacokinetic%20Studies%20in%20Adult%20Rats&rft.jtitle=Pharmaceutical%20research&rft.au=Phan,%20Guillaume&rft.date=2018-12-01&rft.volume=35&rft.issue=12&rft.spage=227&rft.epage=12&rft.pages=227-12&rft.artnum=227&rft.issn=0724-8741&rft.eissn=1573-904X&rft_id=info:doi/10.1007/s11095-018-2515-1&rft_dat=%3Cgale_hal_p%3EA724210167%3C/gale_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c516t-be64371e731940b489320dc7afafd882596ab5564eadabdc0c74a855fac3bf013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2117060331&rft_id=info:pmid/30298383&rft_galeid=A724210167&rfr_iscdi=true |